Rehmann Capital Advisory Group’s ANI Pharmaceuticals ANIP Stock Holding History

Rehmann Capital Advisory Group’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-24	Closed	-$1.97K	–	1701
2019 Q2	$1.97K	Hold	24	–	–	﹤0.01%	1782
2019 Q1	$1.69K	Hold	24	–	–	﹤0.01%	1814
2018 Q4	$1.08K	Hold	24	–	–	﹤0.01%	1629
2018 Q3	$1.36K	Hold	24	–	–	﹤0.01%	1913
2018 Q2	$1.6K	Sell	24 -18	-43%	-$1.12K	﹤0.01%	1856
2018 Q1	$2K	Buy	+42	New	+$2.67K	﹤0.01%	1697

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ICOM

Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Rehmann Capital Advisory Group's ANIP Position: Q3 2019 in Review

Rehmann Capital Advisory Group sold out of ANI Pharmaceuticals (ANIP) in Q3 2019, closing a stake of 24 shares — an estimated $1.97K sold.

Rehmann Capital Advisory Group first reported a position in ANIP in Q1 2018 and held it in 6 quarters. The position peaked at $2K in Q1 2018. 190 funds tracked by Wall St. Rank hold ANIP as of Q3 2019.

Rehmann Capital Advisory Group reported no remaining ANI Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Rehmann Capital Advisory Group sold 24 ANI Pharmaceuticals shares in Q3 2019, an estimated $1.97K.
Rehmann Capital Advisory Group first reported a position in ANI Pharmaceuticals in Q1 2018 and held it in 6 quarters.
Rehmann Capital Advisory Group's ANI Pharmaceuticals position peaked at $2K in Q1 2018.
190 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2019.

Based on Rehmann Capital Advisory Group's 13F filing for Q3 2019, filed 2 Jan 2020.